Bristol Myers drops another CytomX program

Bristol Myers Squibb dropped another CTLA-4 program from its decade-long research collaboration with CytomX after the big pharma reviewed its portfolio.

CytomX announced the change in its 2023 financial results on Monday, noting that the companies are still collaborating on multiple preclinical programs, including T cell…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks